Evidence map›Paper›PMID 22910231›Full record

ArticleAntiviral therapy2013

Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection.

Diala El-Maouche, Shruti H Mehta, Catherine G Sutcliffe, Yvonne Higgins, Michael S Torbenson, Richard D Moore, David L Thomas, Mark S Sulkowski, Todd T Brown

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Diala El-MaoucheNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Shruti H Mehta
Catherine G Sutcliffe
Yvonne Higgins
Michael S Torbenson
Richard D Moore
David L Thomas
Mark S Sulkowski
Todd T Brown
Johns Hopkins University · USJohns Hopkins Medicine · USNational Institutes of Health · US

Funding

Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Bryan Lau · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICER01DA011602 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 1998 to 2013
$10.8M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
MID CAREER INVESTIGATOR AWARDK24DA000432 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2000 to 2009
$1.5M
Alcohol and HIV Treatment and Clinical ProgressionR01AA016893 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2008 to 2011
$1.3M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
Alcohol and HIV Progression in the Hopkins HIV CohortR21AA015032 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2004 to 2005
$388k
NCRR NIH HHS UL1 RR 025005NCRR NIH HHS UL1 RR025005NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R01 AA16893NIAAA NIH HHS R21 AA015032NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069918NIDA NIH HHS K24 DA000432NIDA NIH HHS K24 DA00432NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA011602NIDA NIH HHS R01 DA016065NIDA NIH HHS R01 DA11602NIDA NIH HHS R37 DA013806NIDA NIH HHS U01 DA036935PHS HHS R01 A1093520PHS HHS R37 013806
6 · The paper itself

Abstract

backgroundFractures and cirrhosis are major causes of morbidity and mortality among HIV-HCV-coinfected individuals. It is not known whether vitamin D deficiency is associated with these outcomes.

methodsBetween 2005 and 2007, 116 HIV-HCV-coinfected individuals underwent dual-energy X-ray absorptiometry within 1 year of a liver biopsy. 25-Hydroxyvitamin D (25OHD) and parathyroid hormone were measured from archived samples. Low bone mineral density (BMD) was defined as BMD≥2 standard deviations lower than age-, sex- and race-matched controls (Z-score ≤-2.0) at the total hip, femoral neck or lumbar spine. Histological fibrosis staging was assessed according to the METAVIR system (0 [no fibrosis] to 4 [cirrhosis]).

resultsThe cohort was 87% African-American and 63% male. The median age (IQR) was 49.9 years (46.5-53.3). A total of 89% had a CD4(+) T-cell count >200 cells/mm(3) and 64% were receiving HAART. The median 25OHD was 19 ng/ml (IQR 11.0-26.0). Hypovitaminosis D (25OHD≤15 ng/ml) was present in 41% and secondary hyperparathyroidism, defined by parathyroid hormone >65 pg/ml, was present in 24%. In total, 27% had low BMD (Z-score ≤-2) at the spine, femoral neck or total hip, and 39% had significant hepatic fibrosis (METAVIR≥2). In multivariate analysis, vitamin D deficiency was not associated with significant fibrosis or with BMD at any site.

conclusionsVitamin D deficiency was highly prevalent in this mostly African-American HIV-HCV-coinfected population, but was not related to BMD or liver disease severity. These data suggest that efforts to increase vitamin D levels in this population may not improve bone or liver outcomes.

Indexed as

Bone DensityCoinfectionBlack or African AmericanFemaleHepatitis CHIV InfectionsHumansLiver CirrhosisMaleMiddle AgedPrevalenceRisk FactorsVitamin D Deficiency

Identifiers

PMID22910231
PMCPMC3790468
OpenAlexW2069270112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.